Literature DB >> 24672807

Exploitation of the Macrophage Mannose Receptor (CD206) in Infectious Disease Diagnostics and Therapeutics.

Abul K Azad1, Murugesan V S Rajaram1, Larry S Schlesinger1.   

Abstract

The macrophage mannose receptor (MR, CD206) is a C-type lectin expressed predominantly by most tissue macrophages, dendritic cells and specific lymphatic or endothelial cells. It functions in endocytosis and phagocytosis, and plays an important role in immune homeostasis by scavenging unwanted mannoglycoproteins. More attention is being paid to its particularly high expression in tissue pathology sites during disease such the tumor microenvironment. The MR recognizes a variety of microorganisms by their mannan-coated cell wall, which is exploited by adapted intracellular pathogens such as Mycobacterium tuberculosis, for their own survival. Despite the continued development of drug delivery technologies, the targeting of agents to immune cells, especially macrophages, for effective diagnosis and treatment of chronic infectious diseases has not been addressed adequately. In this regard, strategies that optimize MR-mediated uptake by macrophages in target tissues during infection are becoming an attractive approach. We review important progress in this area.

Entities:  

Year:  2014        PMID: 24672807      PMCID: PMC3963702          DOI: 10.13188/2325-4653.1000003

Source DB:  PubMed          Journal:  J Cytol Mol Biol


  43 in total

Review 1.  The origin and function of tumor-associated macrophages.

Authors:  A Mantovani; B Bottazzi; F Colotta; S Sozzani; L Ruco
Journal:  Immunol Today       Date:  1992-07

2.  A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity.

Authors:  Jennifer S Lam; Michael K Mansour; Charles A Specht; Stuart M Levitz
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

3.  Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes.

Authors:  Yan Lu; Shigeru Kawakami; Fumiyoshi Yamashita; Mitsuru Hashida
Journal:  Biomaterials       Date:  2007-04-05       Impact factor: 12.479

Review 4.  Advances in the development of new tuberculosis drugs and treatment regimens.

Authors:  Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

5.  Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles.

Authors:  Saijie Zhu; Mengmeng Niu; Hannah O'Mary; Zhengrong Cui
Journal:  Mol Pharm       Date:  2013-08-06       Impact factor: 4.939

6.  Tailoring the immune response by targeting C-type lectin receptors on alveolar macrophages using "pathogen-like" amphiphilic polyanhydride nanoparticles.

Authors:  Ana V Chavez-Santoscoy; Rajarshi Roychoudhury; Nicola L B Pohl; Michael J Wannemuehler; Balaji Narasimhan; Amanda E Ramer-Tait
Journal:  Biomaterials       Date:  2012-04-01       Impact factor: 12.479

Review 7.  From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor.

Authors:  Paola Allavena; Marcello Chieppa; Paolo Monti; Lorenzo Piemonti
Journal:  Crit Rev Immunol       Date:  2004       Impact factor: 2.214

8.  SPECT imaging of joint inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis.

Authors:  Stéphanie Put; Steve Schoonooghe; Nick Devoogdt; Evelien Schurgers; Anneleen Avau; Tania Mitera; Matthias D'Huyvetter; Patrick De Baetselier; Geert Raes; Tony Lahoutte; Patrick Matthys
Journal:  J Nucl Med       Date:  2013-02-27       Impact factor: 10.057

9.  Investigations into an alternate approach to target mannose receptors on macrophages using 4-sulfated N-acetyl galactosamine more efficiently in comparison with mannose-decorated liposomes: an application in drug delivery.

Authors:  Deepak Singodia; Ashwni Verma; Rahul K Verma; Prabhat Ranjan Mishra
Journal:  Nanomedicine       Date:  2011-07-23       Impact factor: 5.307

10.  Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages.

Authors:  P Allavena; M Chieppa; G Bianchi; G Solinas; M Fabbri; G Laskarin; A Mantovani
Journal:  Clin Dev Immunol       Date:  2011-02-09
View more
  62 in total

1.  Polymer-augmented liposomes enhancing antibiotic delivery against intracellular infections.

Authors:  Fang-Yi Su; Jasmin Chen; Hye-Nam Son; Abby M Kelly; Anthony J Convertine; T Eoin West; Shawn J Skerrett; Daniel M Ratner; Patrick S Stayton
Journal:  Biomater Sci       Date:  2018-06-25       Impact factor: 6.843

2.  Surface-engineered dendrimeric nanoconjugates for macrophage-targeted delivery of amphotericin B: formulation development and in vitro and in vivo evaluation.

Authors:  Keerti Jain; Ashwni Kumar Verma; Prabhat Ranjan Mishra; Narendra Kumar Jain
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

Review 3.  Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.

Authors:  Humzah Jamshaid; Fakhar Ud Din; Gul Majid Khan
Journal:  J Nanobiotechnology       Date:  2021-04-15       Impact factor: 10.435

Review 4.  From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity.

Authors:  Natalie L Trevaskis; Lisa M Kaminskas; Christopher J H Porter
Journal:  Nat Rev Drug Discov       Date:  2015-10-16       Impact factor: 84.694

5.  Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis.

Authors:  Banishree Saha; David Tornai; Karen Kodys; Adeyinka Adejumo; Patrick Lowe; Craig McClain; Mack Mitchell; Arthur McCullough; Srinivasan Dasarathy; Aimee Kroll-Desrosiers; Bruce Barton; Svetlana Radaeva; Gyongyi Szabo
Journal:  Hepatology       Date:  2019-05-27       Impact factor: 17.425

Review 6.  The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach.

Authors:  Frederick O Cope; Bonnie Abbruzzese; James Sanders; Wendy Metz; Kristyn Sturms; David Ralph; Michael Blue; Jane Zhang; Paige Bracci; Wiam Bshara; Spencer Behr; Toby Maurer; Kenneth Williams; Joshua Walker; Allison Beverly; Brooke Blay; Anirudh Damughatla; Mark Larsen; Courtney Mountain; Erin Neylon; Kaeli Parcel; Kapil Raghuraman; Kevin Ricks; Lucas Rose; Akhilesh Sivakumar; Nicholas Streck; Bryan Wang; Christopher Wasco; Larry S Schlesinger; Abul Azad; Murugesan V S Rajaram; Wael Jarjour; Nicholas Young; Thomas Rosol; Amifred Williams; Michael McGrath
Journal:  Nucl Med Biol       Date:  2015-12-03       Impact factor: 2.408

Review 7.  Novel Approaches for the Treatment of Pulmonary Tuberculosis.

Authors:  Zhi Ming Tan; Gui Ping Lai; Manisha Pandey; Teerapol Srichana; Mallikarjuna Rao Pichika; Bapi Gorain; Subrat Kumar Bhattamishra; Hira Choudhury
Journal:  Pharmaceutics       Date:  2020-12-10       Impact factor: 6.321

Review 8.  Macrophage immunoregulatory pathways in tuberculosis.

Authors:  Murugesan V S Rajaram; Bin Ni; Claire E Dodd; Larry S Schlesinger
Journal:  Semin Immunol       Date:  2014-10-30       Impact factor: 11.130

9.  Newly synthesized surfactants for surface mannosylation of respirable SLN assemblies to target macrophages in tuberculosis therapy.

Authors:  Eleonora Maretti; Luca Costantino; Francesca Buttini; Cecilia Rustichelli; Eliana Leo; Eleonora Truzzi; Valentina Iannuccelli
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

10.  Nanotechnological Approaches to Immunosuppression and Tolerance Induction.

Authors:  Kunal Patel; Carl Atkinson; Danh Tran; Satish N Nadig
Journal:  Curr Transplant Rep       Date:  2017-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.